Palmitoyl Tetrapeptide-7 vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Palmitoyl Tetrapeptide-7Anti-Aging & Longevity
Prostamax- Summary
- Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- Topical penetration-dependent; effects last hours to days
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 2-5 ppm concentration in formulation
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Reduces IL-6 inflammatory cytokine in skin
- Prevents 'inflammaging' of the skin
- Inhibits MMP collagen-degrading enzymes
- Synergistic with Matrixyl for anti-aging
- Clinically tested for wrinkle and skin texture improvement
- Well-tolerated topically
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Contact sensitization (rare)
- Well-tolerated at standard concentrations
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —